44<strong>AstraZeneca</strong> <strong>Annual</strong> <strong>Review</strong> <strong>2005</strong>SHAREHOLDER INFORMATION CONTINUEDSHAREVIEW<strong>AstraZeneca</strong>’s shareholders with internet accessmay visit shareview.co.uk and register theirdetails to create a portfolio. Shareview is a freeand secure on-line service from Lloyds TSBRegistrars that gives access to shareholdingsincluding balance movements, indicative shareprices and information about recent dividends.SHAREGIFT<strong>AstraZeneca</strong> welcomes and values all itsshareholders, no matter how many or how fewshares they own. However, shareholders whohave only a small number of shares whose valuemakes it uneconomic to sell them, either now orat some stage in the future, may wish to considerdonating them to charity through ShareGift,an independent charity share donation scheme.One feature of the scheme is that there is no gainor loss for capital gains tax purposes on giftsof shares through ShareGift and it may now alsobe possible to obtain income tax relief on thedonation. Further information about ShareGiftcan be found on its website, sharegift.org,or by contacting ShareGift on 020 7337 0501or at 46 Grosvenor Street, London W1K 3HN.More information about the tax position on giftsof shares to ShareGift can be obtained fromHM Revenue & Customs whose websiteaddress is hmrc.gov.uk. The share transfer formneeded to make a donation may be obtainedfrom the <strong>AstraZeneca</strong> Registrar, Lloyds TSBRegistrars whose address can be found onthe back cover of this document. ShareGift isadministered by The Orr Mackintosh Foundation,registered charity number 1052686.THE UNCLAIMED ASSETS REGISTER<strong>AstraZeneca</strong> supplies unclaimed dividenddata to the Unclaimed Assets Register (UAR)which provides investors who have lost trackof shareholdings with an opportunity to searchthe UAR’s database of unclaimed financial assetson payment of a small, fixed fee.The UAR donatespart of the search fee to charity. The UAR canbe contacted at Bain House, 16 ConnaughtPlace, London W2 2ES and at uar.co.uk.
The contents of this <strong>AstraZeneca</strong> <strong>Annual</strong> <strong>Review</strong>are derived wholly and exclusively from the<strong>AstraZeneca</strong> <strong>Annual</strong> Report and Form 20-FInformation for the financial year ended 31December <strong>2005</strong> to which the reader is referredfor additional analytical information.TRADE MARKSTrade marks of the <strong>AstraZeneca</strong> group ofcompanies appear throughout this documentin italics. <strong>AstraZeneca</strong>, the <strong>AstraZeneca</strong> logotypeand the <strong>AstraZeneca</strong> symbol are all trade marksof the <strong>AstraZeneca</strong> group of companies.USE OF TERMSIn this <strong>Annual</strong> <strong>Review</strong> <strong>2005</strong>, unless the contextotherwise requires, ‘<strong>AstraZeneca</strong>’, ‘the Group’,‘the Company’, ‘we’, ‘us’ and ‘our’ refer to<strong>AstraZeneca</strong> PLC and its consolidated entities.STATEMENTS OF COMPETITIVE POSITIONExcept as otherwise stated, market informationin this <strong>Annual</strong> <strong>Review</strong> <strong>2005</strong> regarding the positionof our business or products relative to its or theircompetition is based upon published statisticaldata for the 12 months ended 30 September<strong>2005</strong>, obtained from IMS Health, a leadingsupplier of statistical data to the pharmaceuticalindustry. Except as otherwise stated, thesemarket share and industry data from IMS Healthhave been derived by comparing our salesrevenue to competitors’ and total market salesrevenues for that period.STATEMENTS OF GROWTH RATESExcept as otherwise stated, growth rates inthis <strong>Annual</strong> <strong>Review</strong> <strong>2005</strong> are given at constantexchange rates (CER).CAUTIONARY STATEMENT REGARDINGFORWARD-LOOKING STATEMENTSIn order to utilise the ‘safe harbour’ provisionsof the US Private Securities Litigation ReformAct 1995, we are providing the followingcautionary statement: This <strong>Annual</strong> <strong>Review</strong> <strong>2005</strong>contains certain forward-looking statementsabout <strong>AstraZeneca</strong>. Although we believe ourexpectations are based on reasonableassumptions, any forward-looking statementsmay be influenced by factors that could causeactual outcomes and results to be materiallydifferent from those predicted. We identify theforward-looking statements by using the words‘anticipates’, ‘believes’, ‘expects’, ‘intends’and similar expressions in such statements.These forward-looking statements are subjectto numerous risks and uncertainties. Importantfactors that could cause actual results to differmaterially from those contained in forwardlookingstatements, certain of which are beyondour control, include, among other things:the loss or expiration of patents, marketingexclusivity or trade marks; exchange ratefluctuations; the risk that R&D will not yield newproducts that achieve commercial success;the impact of competition, price controls andprice reductions; taxation risks; the risk ofsubstantial product liability claims; the impactof any failure by third parties to supply materialsor services; the risk of delay to new productlaunches; the difficulties of obtaining andmaintaining governmental approvals forproducts; the risk of failure to observe ongoingregulatory oversight; the risk that new productsdo not perform as we expect; and the riskof environmental liabilities.ASTRAZENECA WEBSITESInformation on our websites, includingastrazeneca.com, astrazenecaclinicaltrials.comand rosuvastatininformation.com, does notform part of this document.The paper used in this <strong>Review</strong> is sourced from sawmillresidues, forest thinning and sustainable forests. All millbroke is recycled and accounts for up to 30% of the totalfibre content. The pulp is bleached using a chlorine-free(ECF) process. This product meets ISO 9706 requirements.©<strong>AstraZeneca</strong> PLC 2 February 2006Designed by Addison Corporate Marketing Ltd.